

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6189903

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
OPSONA THERAPEUTICS LIMITED	05/21/2020
RECEIVING PARTY DATA	
Name:	NEURAMEDY CO., LTD.
Street Address:	RM408, CONVERGENCE RESEARCH CENTER, COLLEGE OF MEDICINE, SNU
Internal Address:	103 DAEHAK-RO, JONGNO-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	03080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9234046
CORRESPONDENCE DATA	
Fax Number:	(617)646-8646
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6176468000
Email:	Caroline.Kerressey@WolfGreenfield.com, Patents_RoqueE@WolfGreenfield.com
Correspondent Name:	ROQUE EL-HAYEK
Address Line 1:	WOLF, GREENFIELD & SACKS, P.C.
Address Line 2:	600 ATLANTIC AVENUE
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	O0294.70002US02
NAME OF SUBMITTER:	ROQUE EL-HAYEK
SIGNATURE:	/Roque El-Hayek/
DATE SIGNED:	07/08/2020
Total Attachments: 11	
source=O029470002US02-ASI-RE#page1.tif	
source=O029470002US02-ASI-RE#page2.tif	

source=O029470002US02-ASI-RE#page3.tif
source=O029470002US02-ASI-RE#page4.tif
source=O029470002US02-ASI-RE#page5.tif
source=O029470002US02-ASI-RE#page6.tif
source=O029470002US02-ASI-RE#page7.tif
source=O029470002US02-ASI-RE#page8.tif
source=O029470002US02-ASI-RE#page9.tif
source=O029470002US02-ASI-RE#page10.tif
source=O029470002US02-ASI-RE#page11.tif

ASSIGNMENT

THIS ASSIGNMENT is made between

(i) ...Opsona Therapeutics Limited..... having an address of ... Second Floor, Ashford House, Tara Street, Dublin 2, Ireland ... (hereinafter called the "Assignor"); and

(ii) ...Neuramedy Co., LTD. having an address of ...Rm408, Convergence Research Center, College of Medicine, SNU, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea... (hereinafter called the "Assignee").

WHEREAS the Assignor is the proprietor of the Patents and Patent Applications shown in the attached Schedule ("the Patent Rights");

AND WHEREAS the Assignee is desirous of obtaining full and exclusive rights in and to the Patent Rights.

WHEREIN Kieran Wallace as chartered accountant of KPMG, 1 Stokes Place, St Stephen's Green, Dublin 2 (hereinafter called the "Liquidator"), was appointed as liquidator of the Assignor on 24 January 2019.

NOW THEREFORE in consideration of One Euro (€1) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby:

1 Assigns to the Assignee such right title and interest as it has in the Patent Rights, and all the rights, powers, privileges and liabilities conferred on the proprietor thereof by the grant of the Patent Rights, including the right to sue for damages and other remedies in respect of any infringement of the Patent Rights which may have occurred prior to the date hereof.

Without prejudice to the generality of the foregoing, the rights hereby assigned include the right (if any) to claim priority under the Paris Convention.

- 2 Agrees to execute all such further documents and do all such further things as may be necessary or proper for giving effect to the foregoing.
- 3 This assignment shall be effective as of the last date of signature hereon.

EXCLUSION OF LIABILITY:

a. The Assignee hereby expressly acknowledges that any liability of the Assignor arising out of or in connection with the terms and provisions of this assignment or any agreement or matter connected therewith is hereby excluded and the Assignor shall not be under any liability to the Assignee affecting the Patent Rights.


b. The Assignee hereby expressly acknowledges that the Liquidator is executing this assignment in his capacity as liquidator of the Assignor only for the sole purpose of facilitating an arrangement in relation to the assignment by the Assignor of such right, title or interest as the Assignor may have in the Patent Rights and further acknowledges that any personal liability of the Liquidator and / or other partner of the Liquidator's firm arising out of or in connection with the terms and provisions of this assignment or any agreement or matter connected therewith is hereby excluded and the Liquidator and / or any other partner of the Liquidator's firm shall not be under any liability to the Assignee affecting the assets of the Liquidator or any other partner of the Liquidator's firm personally or their agents or their estate.

EXCLUSION OF REPRESENTATIONS / WARRANTIES:

Such right title and interest in the Patent Rights being assigned pursuant to this assignment are, to the greatest extent permitted by applicable law, provided without warranty of any kind, and any and all warranties, representations, terms and conditions, whether written or oral, express or implied, statutory or otherwise, are hereby excluded by the Assignor.

Executed this 21st day of May 2020.....

for and on behalf ofOpsona Therapeutics Limited..... as the Assignor



Signature

Name ...Kieran Wallace

Position ...Liquidator of Opsona Therapeutics Limited/Insolvency Practitioner of KPMG

Witness Signature IAN BARNETT

Witness Name IAN BARNETT

Position ACCOUNTANT, 1 STOKES PLACE, DUBLIN 2

Executed this 12 day of Feb 2020.....

for and on behalf of ... Neuramedy Co., LTD. .. as the Assignee

Signature

NameSeung-Jae Lee.....

PositionCEO of Neuramedy Co., LTD.

Witness Signature

Witness NameJun. Sung Lee.....

PositionHead of Research, Neuramedy Co., LTD.....

Schedule
"the Patent Rights"

Country	IP Title	Application No.	Publication No./Grant No.
Australia	"Composition and Method for Treatment of Autoimmune Disease"	2008267151	2008267151
Australia	"Compounds and Methods for the Treatment of Renal Disease"	2008270218	2008270218
Australia	HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF	2010270241	2010270241
Australia	Use of TLR-2 Antagonists for Treatment of Reperfusion Injury and Tissue Damage	2008285626	2008285626
Belgium	Anticorps humanisés contre le récepteur Toll 2 et leurs utilisations	10728262.6	2451842B
Belgium	Anticorps humanisés contre le récepteur Toll 2 et leurs utilisations	14158199.1	2805973B
Brazil	HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF	PI1014016-6	
Canada	"Compounds and Methods for the Treatment of Renal Disease"	2692509	2692509
Canada	Anti-Toll-Like Receptor 2 antibodies for use in the Treatment of Cardiac Inflammatory Conditions	2693237	2693237
Canada	Composition and Method for Treatment of	2691784	2691784

	Autoimmune Disease		
Canada	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	2766996	2766996
China	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	201080035690.4	ZL201080035690.4
Europe	"Compounds and Methods for the Treatment of Renal Disease"	08785937.7	2167129B
Europe	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	10728262.6	2451842B
Europe	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	14158199.1	2805973B
Europe	Methods and Compositions for The Treatment of Myelodysplastic Syndrome	17723305.3	
Europe	Methods and Compositions for the Treatment of Ovarian Cancer	18178651.8	
Europe	Methods and Compositions for the Treatment of Pancreatic Cancer	13771469.7	2909236B
Europe	Toll-Like Receptor 2 Binding Epitope and Binding Members Thereto	13713440.9	2831107B
Europe	Use of TLR-2 Antagonists for Treatment of Reperfusion Injury and Tissue Damage	08786862.6	2170366B
France	"Composition et procédé pour le traitement d'une	08786862.6	2170366B

	lésion de reperfusion et d'un dommage tissulaire"		
France	Anticorps humanisés contre le récepteur Toll 2 et leurs utilisations	10728262.6	2451842B
France	Anticorps humanisés contre le récepteur Toll 2 et leurs utilisations	14158199.1	2805973B
France	Composés et procédés pour le traitement d'une maladie rénale	08785937.7	2167129B
France	Epitope de liaison de récepteur Toll-like 2 et composants de liaison à celui-ci	13713440.9	2831107B
France	Methods and Compositions for the Treatment of Pancreatic Cancer	13771469.7	2909236B
Germany	"Verwendung eines TLR-2 Antagonisten zur Behandlung von Reperusionsverletzungen und Gewebeschäden"	602008028593.6	2170366B
Germany	Humanisierte Antikörper gegen Toll-Like-Rezeptor 2 und ihre Verwendung	602010016082.3	2451842B
Germany	Humanisierte Antikörper gegen Toll-like-Rezeptor 2 und ihre Verwendungen	602010046646.9	2805973B
Germany	Methods and Compositions for the Treatment of Pancreatic Cancer	602013048134.2	2909236B
Germany	Toll-like-Rezeptor-2 bindendes Epitop und Bindungselemente dafür	602013031606.6	2831107B
Germany	Verbindungen und Verfahren zur Behandlung von Nierenerkrankungen	602008038630.9	2167129B

India	Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof	938/DELNP/2012	
Ireland	"Use of TLR-2 Antagonists for Treatment of Reperfusion Injury and Tissue Damage"	08786862.6	2170366B
Ireland	Compounds and Methods for the Treatment of Renal Disease	08785937.7	2167129B
Ireland	Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof	10728262.6	2451842B
Ireland	Humanised Antibodies to Toll-like Receptor 2 and Uses Thereof	14158199.1	2805973B
Ireland	Methods and Compositions for the Treatment of Pancreatic Cancer	13771469.7	2909236B
Ireland	Toll-Like Receptor 2 Binding Epitope and Binding Members Thereto	13713440.9	2831107B
Israel	Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof	217225	217225
Italy	"Use of TLR-2 Antagonists for Treatment of Reperfusion Injury and Tissue Damage"	502014902227787	2170366B
Italy	Compounds and Methods for the Treatment of Renal Disease	502015000052070	2167129B
Italy	Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof	502014902284073	2451842B
Italy	Humanised Antibodies to Toll-like Receptor 2 and Uses Thereof	502018000004141	2805973B

Italy	Methods and Compositions for the Treatment of Pancreatic Cancer	502019000032439	2909236B
Italy	Toll-Like Receptor 2 Binding Epitope and Binding Members Thereto	502018000009819	2831107B
Japan	"Composition and Method for Treatment of Autoimmune Disease"	2010-513952	5554703
Japan	HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF	2012-518974	5847707
Japan	HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF	2015-169427	
Japan	Methods And Compositions For The Treatment Of Myelodysplastic Syndrome	2019-529608	
Japan	Use of TLR-2 Antagonists for Treatment of Reperfusion Injury and Tissue Damage	2010-518699	5376275
Mexico	HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF	MX/A/2012/000316	323042
Netherlands	Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof	10728262.6	2451842B
Netherlands	Humanised Antibodies to Toll-like Receptor 2 and Uses Thereof	14158199.1	2805973B
New Zealand	HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND	597447	597447

	USES THEREOF		
New Zealand	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	615441	615441
Patent Co- operation Treaty (PCT)	"Composition and Method for Treatment of Autoimmune Disease"	PCT/EP2008/058339	WO2009/000929
Patent Co- operation Treaty (PCT)	"Compounds and Methods for the Treatment of Renal Disease"	PCT/EP2008/058732	WO2009/004094
Patent Co- operation Treaty (PCT)	"Humanised Antibody and Uses Thereof"	PCT/EP2010/059677	WO2011/003925
Patent Co- operation Treaty (PCT)	"Toll-like receptor 2 binding epitope and binding members thereto"	PCT/EP2013/056824	WO2013/144345
Patent Co- operation Treaty (PCT)	"Use of TLR-2 Antagonists for Treatment of Reperfusion Injury and Tissue Damage"	PCT/EP2008/060249	WO2009/019260
Patent Co- operation Treaty (PCT)	Methods and Compositions for The Treatment of Myelodysplastic Syndrome	PCT/EP2017/060339	
Patent Co- operation Treaty (PCT)	Methods and Compositions for the Treatment of Ovarian Cancer	PCT/EP2019/065838	
Patent Co- operation Treaty (PCT)	Methods and Compositions for the Treatment of Pancreatic Cancer	PCT/EP2013/070410	WO2014/060210
Russia	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	2011153932	2563344
South Africa	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	2012/00273	2012/00273

South Korea	HUMANISED ANTIBODIES TO TOLL- LIKE RECEPTOR 2 AND USES THEREOF	10-2012-7003134	10-1572171
Spain	Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof	10728262.6	2451842B
Spain	Humanised Antibodies to Toll-like Receptor 2 and Uses Thereof	14158199.1	2805973B
Switzerland	Anticorps humanisés contre le récepteur Toll 2 et leurs utilisations	10728262.6	2451842B
Switzerland	Anticorps humanisés contre le récepteur Toll 2 et leurs utilisations	14158199.1	2805973B
United Kingdom	"Use of TLR-2 Antagonists for Treatment of Reperfusion Injury and Tissue Damage"	08786862.6	2170366B
United Kingdom	Compounds and Methods for the Treatment of Renal Disease	08785937.7	2167129B
United Kingdom	Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof	10728262.6	2451842B
United Kingdom	Humanised Antibodies to Toll-like Receptor 2 and Uses Thereof	14158199.1	2805973B
United Kingdom	Methods and Compositions for the Treatment of Pancreatic Cancer	13771469.7	2909236B
United Kingdom	Toll-Like Receptor 2 Binding Epitope and Binding Members Thereto	13713440.9	2831107B
United States	"Composition and Method for Treatment of Autoimmune Disease"	12/666442	8580255

United States	"Compounds and Methods for the Treatment of Renal Disease"	13/526873	9234046
United States	Composition and Method For Treatment of Reperfusion Injury And Tissue Damage	12/671810	8734788
United States	HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF	13/382044	8734794
United States	Methods And Compositions For The Treatment Of Myelodysplastic Syndrome	16/466539	
United States	Methods and Compositions for the Treatment of Pancreatic Cancer	15/244833	10047164
United States	Toll-Like Receptor 2 Binding Epitope and Binding Members Thereto	14/384824	9896497